Zatebradine HCl
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 561430

CAS#: 91940-87-3

Description: Zatebradine HCl is a bradycardic agent. It blocks hyperpolarization-activated inward current (If) through cyclic nucleotide-gated cation (HCN) channels in sinoatrial node cells.


Chemical Structure

img
Zatebradine HCl
CAS# 91940-87-3

Theoretical Analysis

MedKoo Cat#: 561430
Name: Zatebradine HCl
CAS#: 91940-87-3
Chemical Formula: C26H37ClN2O5
Exact Mass:
Molecular Weight: 493.04
Elemental Analysis: C, 63.34; H, 7.56; Cl, 7.19; N, 5.68; O, 16.22

Price and Availability

Size Price Availability Quantity
5.0mg USD 230.0 2 Weeks
10.0mg USD 390.0 2 Weeks
25.0mg USD 730.0 2 Weeks
Bulk inquiry

Synonym: Zatebradine HCl; Zatebradine Hydrochloride; UL-FS49; UL FS49; ULFS49;

IUPAC/Chemical Name: 3-[3-[2-(3,4-Dimethoxyphenyl)ethyl-methylamino]propyl]-7,8-dimethoxy-2,5-dihydro-1H-3-benzazepin-4-one hydrochloride

InChi Key: ZRNKXJHEQKMWCH-UHFFFAOYSA-N

InChi Code: InChI=1S/C26H36N2O5.ClH/c1-27(13-9-19-7-8-22(30-2)23(15-19)31-3)11-6-12-28-14-10-20-16-24(32-4)25(33-5)17-21(20)18-26(28)29;/h7-8,15-17H,6,9-14,18H2,1-5H3;1H

SMILES Code: O=C1CC2=CC(OC)=C(OC)C=C2CCN1CCCN(CCC3=CC=C(OC)C(OC)=C3)C.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 493.04 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Bois P, Guinamard R, Chemaly AE, Faivre JF, Bescond J. Molecular regulation and pharmacology of pacemaker channels. Curr Pharm Des. 2007;13(23):2338-49. Review. PubMed PMID: 17692005.

2: Schipke JD, Büter I, Hohlfeld T, Schmitz-Spanke S, Gams E. [Selective I(f) channel inhibition: an alternative for treating coronary artery disease?]. Herz. 2006 Feb;31(1):55-74. Review. German. PubMed PMID: 16502273.

3: Cerbai E, Mugelli A. [The pacemaker current If: a novel pharmacological target for cardiologists]. Ital Heart J Suppl. 2005 Jul;6(7):413-9. Review. Italian. PubMed PMID: 16082824.

4: Berdeaux A, Colin P, Monnet X, Ghaleh B. [Heart rate and experimental myocardial ischaemia]. Therapie. 2004 Sep-Oct;59(5):507-10. Review. French. PubMed PMID: 15648302.

5: Yusuf S, Camm AJ. Sinus tachyarrhythmias and the specific bradycardic agents: a marriage made in heaven? J Cardiovasc Pharmacol Ther. 2003 Jun;8(2):89-105. Review. PubMed PMID: 12808482.

6: De Clerck F, Van de Water A, D'Aubioul J, Lu HR, van Rossem K, Hermans A, Van Ammel K. In vivo measurement of QT prolongation, dispersion and arrhythmogenesis: application to the preclinical cardiovascular safety pharmacology of a new chemical entity. Fundam Clin Pharmacol. 2002 Apr;16(2):125-40. Review. PubMed PMID: 12031065.

7: Schipke JD, Harasawa Y, Sugiura S, Alexander J Jr, Burkhoff D. Effect of a bradycardic agent on the isolated blood-perfused canine heart. Cardiovasc Drugs Ther. 1991 Apr;5(2):481-8. Review. PubMed PMID: 1854656.

8: Kobinger W, Lillie C. Specific bradycardic agents--a novel pharmacological class? Eur Heart J. 1987 Dec;8 Suppl L:7-15. Review. PubMed PMID: 2897916.